“Carcinogenicity studies were not conducted for sevabertinib and are not warranted for the proposed indication.”
✓ VerifiedFDA multi-discipline review, p. 44Source ↗
Reproductive & developmental
Rat EFD: maternal toxicity and reduced fetal weights at ≥6 mg/kg/day (≥0.18x human AUC)
“Sevabertinib treatment resulted in maternal toxicity (reduced body weight and body weight gain) and a reduction in fetal weights at ≥6 mg/kg/day (≥0.18 times the human exposure based on AUC at the clinical dose).”
No major acute effects on dog telemetry hemodynamics, rat CNS function or rat respiratory function
“Sevabertinib, at single oral doses, was devoid of major acute effects (i) on hemodynamic parameters in a dog telemetry study (Module 4.2.1.3, R-14051), (ii) on parameters of CNS function (behavior, locomotor activity, and body temperature) in rats”
✓ VerifiedFDA multi-discipline review, p. 56Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative